与会专家指出，针对核能行业特性，金融机构可通过灵活设计增发、可转债、境内外债券等多元化融资产品，并结合绿色、转型与可持续金融标签，协助包 括中核国际在内的央企拓展融资渠道与国际投资者群体。同时，香港市场完善的制度体系和丰富的国际投资资源，为央企加速海外布局提供了坚实支撑。 会议还就海外监管环境、境外项目风险管理及资本市场建设等议题进行了充分交流。各方一致表示，中核国际与中银国际将以此次研讨会为契机，进一步加 强协作，共同推动中国核能产业链在香港资本市场获得更多支持，为中国核能产业持续健康安全发展贡献力量。 来源：中核国际有限公司 中核集团与中核国际代表介绍了公司在海外资源获取与市场拓展方面的最新进展。作为中核集团打造的天然铀海外平台，中核国际近年来在天然铀贸易、境 外股权合作及资本市场交流等方面奠定业务基础，正持续借助港股平台提升资本运作能力，并通过加强与市场的沟通，提升市场对核能及天然铀行业的关 注。 中银国际代表分享了在天然铀与矿业资本市场领域的实践经验，多次为中外矿业及能源企业完成股权配售、可转债发行等融资项目，积累了丰富的境外矿业 融资与并购服务经验。 8月22日，为贯彻落实国家能源安全战略，积极响应 ...

Group 1 - The company, China Nuclear International (02302), announced a general financing agreement with China Nuclear Finance Management Co., Ltd. [1] - Under this agreement, China Nuclear Finance will provide up to $50 million in committed financing for the company's uranium trading business [1]

Group 1 - The core point of the article is that China National Nuclear Corporation International (中核国际) has entered into a general financing agreement with China National Nuclear Finance Management Co., Ltd. (中核财资) to secure up to 50 million USD in committed financing for its uranium trading business [1] Group 2 - The financing is intended to support the company's uranium trading operations, indicating a strategic move to enhance its capabilities in this sector [1] - The agreement is set to be effective until August 21, 2025, providing a clear timeline for the financing arrangement [1]

格隆汇8月21日丨中核国际(02302.HK)公告，于2025年8月21日，公司与中核财资管理有限公司("中核财 资")订立一般融资协议，据此，中核财资会向公司提供高达5000万美元的已承诺融资，用于集团铀贸易 业务。 ...

香港交易及結算所有限公司及香港聯合交易所有限公司（「聯交所」）對本公告的內容 概不負責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告 全部或任何部份內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 本公司董事（「董事」）局（「董事局」）宣佈，於二零二五年八月二十一日，本公司與中 核財資管理有限公司（「中核財資」）訂立一般融資協議，據此，中核財資會向本公司 提供高達50,000,000美元的已承諾融資（「中核融資」），用於本集團鈾貿易業務。 CNNC INTERNATIONAL LIMITED 中核國際有限公司 （於開曼群島註冊成立之有限公司） （股份代號：2302） 根據上市規則第13.18條所作披露 本公告由中核國際有限公司（以下簡稱「本公司」，連同其附屬公司統稱「本集團」）根 據香港聯合交易所有限公司上市規則（「上市規則」）第13.18條作出。 融資協議 該筆融資會根據融資協議的條款，由二零二五年八月二十一日至二零二六年八月二 十日期間可供提取。每次提取融資後，均須於本公司與中核財資互相協定的日子內 償還，而所有就融資的未償還款項的最後還款日期，不得超逾二零二六年八月二十 日。 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其 準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告的全部或任何部份內 容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 CNNC INTERNATIONAL LIMITED 中核國際有限公司 （於開曼群島註冊成立之有限公司） （股份代號：2302） 董事局會議通告 於本公告日期，董事局包括非執行董事暨主席：王成先生；執行董事暨行政總 裁：張義先生；非執行董事：吳戈先生及孫若凡先生；以及獨立非執行董事： 崔利國先生、陳以海先生及劉亞潔女士。 中核國際有限公司（「本公司」）之董事（「董事」）局（「董事局」）宣佈 本公司之董事局會議將於二零二五年八月二十六日（星期二）舉行，旨在（其 中包括）審議及批准本公司及其附屬公司截至二零二五年六月三十日止六個月 之中期業績公告及其發佈。 承董事局命 CNNC International Limited 中核國際有限公司 主席 王成 香港，二零二五年八月十四日 ...

致：香港交易及結算所有限公司 公司名稱: 中核國際有限公司 呈交日期: 2025年8月1日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02302 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 1,000,000,000 | HKD | | 0.01 | HKD | | 10,000,000 | | 增加 / 減少 (-) | | | | | | | HKD | | | | 本月底結存 | | | 1,000,000,000 | HKD | | 0.01 | HKD | | 10,000,000 | 本月底法定/註冊股本總額： HKD 10,000,000 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 | | | FF ...

Core Viewpoint - 中核国际预计2025年半年度收入将显著增长，毛利和净利润也将实现大幅改善 [1] Financial Performance - 预计2025年半年度收入将达到不少于5.85亿港元，毛利将不少于1300万港元 [1] - 2024年同期收入和毛利分别为约640万港元 [1] - 预计2025年半年度股东应占净利润将不少于950万港元，扭转2024年半年度的净亏损约770万港元 [1] Business Growth Drivers - 收入增长主要得益于铀贸易业务交易量的大幅增加，绝大部分收入来自与独立第三方的天然铀贸易 [1] - 由于2024年下半年及2025年半年度现货铀价格相对稳定，集团能够在风险可控的前提下增加铀贸易业务 [1]

Group 1 - The core viewpoint of the article highlights that China Nuclear International (02302) has experienced a significant stock price increase of over 5%, currently trading at 3.9 HKD with a transaction volume of 1.6637 million HKD [1] - The company anticipates a substantial increase in revenue for the first half of 2025, projecting it to reach at least approximately 585 million HKD, compared to around 64 million HKD for the same period in 2024 [1] - The gross profit for the first half of 2025 is expected to rise to at least approximately 13 million HKD, a significant increase from the gross profit of around 640,000 HKD in the first half of 2024 [1] Group 2 - The company forecasts a turnaround from a net loss attributable to shareholders of approximately 7.7 million HKD in the first half of 2024 to a net profit of at least approximately 9.5 million HKD in the first half of 2025 [1] - This performance improvement is primarily attributed to a substantial increase in the trading volume of uranium business, with most revenue derived from natural uranium trading with independent third parties [1] - The stability of spot uranium prices in the second half of 2024 and the first half of 2025 has allowed the company to expand its uranium trading business with independent third parties while maintaining controllable risks [1]

Performance Updates - 开拓药业-B (09939.HK) has completed patient enrollment for the Phase III clinical trial of KX-826 solution for androgenetic alopecia in adult males in China [2] - 李氏大药厂 (00950.HK) has received approval from the National Medical Products Administration for Socazolimab to be used in combination with chemotherapy for first-line treatment of extensive-stage small cell lung cancer in mainland China [2] - 恒瑞医药 (01276.HK) has received approval for clinical trials of SHR-8068 injection, Adebali monoclonal antibody injection, and Bevacizumab injection [2] - 恒瑞医药 (01276.HK) has also received approval to conduct clinical trials for HRS-5041, intended for prostate cancer treatment [2] - 深圳高速公路股份 (00548.HK) reported toll revenue of 106 million yuan for the outer ring project in June [2] - 大成生化科技 (00809.HK) has signed an EPC contract with Northeast Electric and Liaoning Electric for boiler renovation projects, with a maximum cost of 129.1 million yuan [2] - 小黄鸭德盈 (02250.HK) has signed a contract to develop an AI marketing system to diversify revenue sources [2] Buyback and Financing Activities - 威海银行 (09677.HK) plans to issue up to approximately 758 million domestic shares and 154 million H-shares, raising nearly 3 billion yuan [2] Financial Results - 香港电讯-SS (06823.HK) reported total revenue of 17.322 billion HKD for the first half, a year-on-year increase of 4%, with a net profit of 2.07 billion HKD, also up 4% [4] - 青岛银行 (03866.HK) reported operating revenue of 7.662 billion yuan for the first half, a growth of 7.5%, and a net profit of 3.065 billion yuan, up 16.05% [4] - 中国石油化工股份 (00386.HK) expects mid-term net profit to be between 20.1 billion and 21.6 billion yuan, a year-on-year decline of 39.5%-43.7% [4] - 汽车之家-S (02518.HK) reported total revenue of 3.212 billion yuan for the first half, a decrease of 7.75%, with a net profit of 772 million yuan, down 15.99% [4] - 绿茶集团 (06831.HK) issued a profit warning, expecting mid-term net profit to be between 230 million and 237 million yuan, a year-on-year increase of approximately 32%-36% [4] - 粤海置地 (00124.HK) issued a profit warning, expecting mid-term net profit to exceed 260 million HKD, turning from loss to profit [4] - 药师帮 (09885.HK) issued a profit warning, expecting mid-term net profit to exceed 70 million yuan [4] - 中国东方教育 (00667.HK) issued a profit warning, expecting mid-term net profit to grow by 45%-50% year-on-year [4] - 中核国际 (02302.HK) issued a profit warning, expecting mid-term revenue to increase to at least 585 million HKD, with net profit of at least 9.5 million HKD [4] - 大唐环境 (01272.HK) issued a profit warning, expecting mid-term net profit to decrease to between 350 million and 400 million yuan [4] - 长江生命科技 (00775.HK) issued a profit warning, expecting mid-term net loss of approximately 150 million HKD, turning from profit to loss year-on-year [4] - 延长石油国际 (00346.HK) issued a profit warning, expecting mid-term loss of approximately 27.9 million HKD [4]